Download Research from University of Miami and Tetra Discovery Shows

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts

Neuropharmacology wikipedia, lookup

Neuropsychopharmacology wikipedia, lookup

Donald O. Hebb wikipedia, lookup

Limbic system wikipedia, lookup

History of neuroimaging wikipedia, lookup

Brain damage wikipedia, lookup

Transcript
ResearchfromUniversityofMiamiandTetraDiscoveryShowsPotentialofNovel
DrugtoImproveMemoryafterTraumaticBrainInjury
UniversityofMiamiMillerSchoolofMedicine/TheMiamiProjecttoCureParalysisandTetra
DiscoveryPartnersStudyPublishedintheJournalofNeuroscience
Miami,FL-July6,2016–Treatingratswithanexperimentaldrugatthreemonthsfollowingatraumatic
braininjury(TBI)improvestheirlearningmemoryability,asreportedinanewstudypublishedonlinetodayin
theJulyeditionofTheJournalofNeuroscience.Thedrug,aselectivephosphodiesterase4subtypeinhibitor
(PDE4B),iscurrentlyunderdevelopmentbyTetraDiscoveryPartners,aprivatelyheldbiotechnologycompany
andisbeingtestedasapotentialtherapyforTBIbyUniversityofMiami/MiamiProjectresearchers.
Thepublication,entitledChronicCognitiveDysfunctionafterTraumaticBrainInjuryisImprovedwitha
Phosphodiesterase4BInhibitor,wasauthoredbyColeenM.Atkins,Ph.D.,AssociateProfessor,Departmentof
NeurologicalSurgery,UniversityofMiami,alongwithW.DaltonDietrich,Ph.D.,ScientificDirector,TheMiami
ProjectandKineticConceptsDistinguishedChairinNeurosurgery,SeniorAssociateDeanforDiscoveryScience
andProfessor,NeurologicalSurgery,NeurologyandCellBiologyandwithMarkE.Gurney,Ph.D.,CEOofTetra
DiscoveryPartners.Inthisstudy,theresearchersreportedthattreatmentwiththePDE4Binhibitorreduced
chroniccognitivedeficitsaftertraumaticbraininjuryandrescueddeficitsinhippocampallong-term
potentiation.TheseresultssuggestthatPDE4Binhibitionhasthepotentialtoimprovelearningandmemory
abilityandoverallfunctioningforpeoplelivingwithTBI.
Traumaticbraininjury(TBI)iscausedbyanimpacttothehead.OneofthemostcommoncomplaintsafterTBI
arelearningandmemorydifficulties.Nearly8outof10TBIsurvivorsfrombraininjurymustcopewithlearning
problemsinthemonthstoyearsafterbraintrauma.However,therearepresentlynoeffectivetreatmentsto
improveTBI-inducedlearningandmemoryimpairments.ThemostsuccessfultreatmentshavebeenRitalinand
Aricept,butneitherarewellproventoimprovelearningafterbraintrauma.
Inthereportedstudy,thescientistslookedatthebrainaftertraumatoidentifywhatchangesinthebrain
occurredasaresult.Theyfoundthatbraintraumainhibitsaproteininneuronsthatiscriticalformemory
formation,CREB.
Duringnormallearningandmemory,thenumberofsynapticconnectionsbetweenneuronsincreasesand
theseconnectionsalsobecomestronger.Theseincreasesinsynapticactivityduringlearningareduetoa
moleculecalledcAMP.ElevatedcAMPthenleadstotheactivationofCREBandmemoryformation.Inthis
study,researchersfoundthatTBIimpairsactivationofCREB.Theteamhypothesizedthatasubtype-selective
PDE4BinhibitorthatraisescAMPlevelsandCREBactivationcouldreversethelearningdeficitsinducedbyTBI.
Totestthishypothesis,theresearchersinducedTBIinratsandleftthemuntreatedforthreemonths.Atthree
monthsaftertheirbraintrauma,theresearcherstreatedtheanimalswithaPDE4Binhibitorandthentested
theirbehavioronlearningandmemorytasks.ThestudyrevealedthattreatmentwiththePDE4Binhibitor
significantlyreversedtheTBI-induceddeficitsinthememory.
“TreatingTBIsurvivorsduringthemonthstoyearsafterbraintraumaisaverypromisingareaofresearchand
severalclinicaltrialsarealreadytacklingthisproblem,byusingdrugsrepurposedfromotherneurological
disorderssuchasAlzheimer’sdisease,”saidDr.Dietrich.“ThisselectivePDE4BinhibitorfromTetraDiscovery
Partnershasgreatpromise,restoringthelearningandmemoryperformanceofTBIanimalstonearlynoninjuredlevels.Thisprojectrepresentsanexcellentexampleofacollaborationbetweenacademicresearchers
studyinganimalmodelsofbraininjuryandabiotechcompanywithexpertiseinhumanclinicaltrials.We
expectthatthiscollaborationwithTetrawillyieldanewclinicaltrialusingthistherapeuticstrategyinhuman
TBIsurvivors.”
PreviouseffortstotargetPDE4asatherapeuticapproachtoTBIhavebeenhamperedbytheuseofnonselectivepan-PDE4inhibitors,whichhavebeenmarredbysignificantside-effects–notablynauseaandemesis.
Inthesestudies,thePDE4B-selectiveinhibitorshowedpositiveeffectsoncognition,withoutemesis.
“WeareveryencouragedbythesepreclinicalstudiesshowingthepotentialofselectiveinhibitionofPDE4Bas
astrategyforrestoringcognitivefunctionduringrecoveryfromTBI,”saidMarkGurney,PresidentandChief
ExecutiveOfficerofTetraDiscoveryPartners.“WelookforwardtocontinuingoureffortswiththeUniversityof
MiamiMillerSchoolofMedicine’sMiamiProjecttoCureParalysistodevelopasuccessfultreatmentforthis
importantmedicalneed.”
ThestudywasfundedbytheNationalInstitutesofHealth,NIH/NINDS.
Dr.AtkinsandDr.Dietrichareco-inventorsonUSPTO8,865,723patentwhichclaimstherapeuticuseofPDE4B
inhibitorsfortreatingbraininjury.TetraDiscoveryPartnersistheownerofthispatentandDr.AtkinsandDr.
Dietrichdonothaveequitystakesinthecompanyorthatpatent.
TheMiamiProjecttoCureParalysis:In1985,BarthA.Green,M.D.andNFLHallofFamelinebacker
NickBuonicontihelpedfoundTheMiamiProjecttoCureParalysisafterNick’sson,Marc,sustaineda
spinalcordinjuryduringacollegefootballgame.Today,TheMiamiProjectistheworld’smost
comprehensivespinalcordinjury(SCI)researchcenter,andadesignatedCenterofExcellenceatthe
UniversityofMiamiMillerSchoolofMedicine.TheMiamiProject’sinternationalteamincludesmore
than300scientists,researchers,cliniciansandsupportstaffwhotakeinnovativeapproachestothe
challengesofspinalcordandbraininjuries.
AboutTetraDiscoveryPartners
TetraDiscoveryPartnersisaclinicalstagebiotechnologycompanydevelopingaportfoliooftherapeutic
productsthatwillbringclarityofthoughttopeoplesufferingfromAlzheimer'sdiseaseandotherbrain
disorders.Tetrausesstructure-guideddrugdesigntodiscovermechanisticallynovel,allostericinhibitorsof
phosphodiesterase4(PDE4),whichplaysakeyroleinmemoryformationandlearning.Tetraisbotha
recipientofaNIHBlueprintNeurotherapeuticsNetworkcooperativeresearchagreement,andalsoreceives
majorfundingthroughtheNationalInstituteonAging,andtheNationalInstituteofMentalHealthSmall
BusinessInnovationResearch(SBIR)program.TetraDiscoveryPartnersisheadquarteredinGrandRapids,
MichiganandmaintainsabusinessofficeinCambridge,Massachusetts.Formoreinformation,pleasevisitthe
company'swebsiteathttp://www.tetradiscovery.com.
###
Contacts:
ScottRoy
TheMiamiProject
(305)243-8939
sroy@miami.edu
JoanKureczka
Kureczka/MartinAssociatesforTetraDiscoveryPartners
(415)821-2413
Joan@kureczka-martin.com